A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | MicrobiomeTrials← Back to trialsNCT07041099
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-10-01Est. Completion: 2028-03-15
Enrollment target: 36 participants Locations- Omega Research, Orlando, Florida, United States
- New York University, Brooklyn, New York, United States
- Regional One, Memphis, Tennessee, United States
- Stryde Research, Plano, Texas, United States
- Tranquil Research, Webster, Texas, United States
- Intermountain, Salt Lake City, Utah, United States
- CHU Brest, Brest, France
- Hopitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France
- CHU Nantes, Nantes, France
- CHU St.-Étienne, Saint-Priest-en-Jarez, France
- CHU Strasbourg-Hautepierre, Strasbourg, France
- University Hospital Erlangen, Erlangen, Germany
- Hannover Medical School, Hanover, Germany
- Fondazione Policlinico Universitario A Gemelli, Roma, Italy
Other microbiome trials you might be interested in
Sjögren´s Disease
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneo…
Peoria, United StatesEst. completion Aug 14, 2029
Primary Sjögren SyndromeSarcopenia
The aim of this study is to evaluate the frequency of probable sarcopenia and sarcopenia in patients with primary Sjögre…
Antalya, Turkey (Türkiye)Est. completion Jul 20, 2025
Amy Gubits, MPH